You are here
The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.
SBC: STRYKAGEN CORPORATION Topic: OD
Abstract Duchenne Muscular Dystrophy (DMD) is a fatal muscle disease with a predicted incidence of 1 in 5000 males. DMD results from mutations in the gene encoding dystrophin, a 427 kDa scaffolding protein responsible for providing a mechanical link between the muscle fiber actin cytoskeleton and laminin in the extracellular matrix. The 7β1 integrin is a transmembrane linkage system in skeleta ...STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
SBC: TRANSGENOMIC, INC. Topic: 103
DESCRIPTION provided by applicant Low level tumor associated somatic DNA mutations can have profound implications for development of metastasis prognosis choice of treatment follow up or early cancer detection Unless they are effectively detected these low level mutations can misinform patient management decisions or become missed opportunities for personalized medicine Widely used tech ...STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health